Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
Stopped Safety
Conditions
- Hepatitis B
- HBV
- Hepatitis B, Chronic
Interventions
- DRUG: Inarigivir soproxil
- DRUG: Nucleoside/nucleotide (NUC) analogue inhibitors
Sponsor
F-star Therapeutics, Inc.
Collaborators